

USE AND COST EVOLUTION OF ADALIMUMAB OVER EIGHT YEARS IN A LOCAL HOSPITAL

J. POQUET-JORNET, M. LLINARES-ESQUERDO, L. YANKOVA-KOMSALOVA, J. MONTE-SERRANO, G.A. CASTILLO-LOPEZ, J. CRUAÑES-MONTFERRER,

P.C. NUÑEZ-MARTINEZ, R.A. GHIGLINO-NOVOA, A.D. AGULLO-PEREZ, P. BESO-MORENO. Hospital of Denia. Denia. Alicante (SPAIN)

Background and Importance

- ✓ Ongoing rise in healthcare costs makes necessary to establish containment strategies.
- ✓ Commitment to improve access to most effective and safest treatments.
- ✓ Biosimilar medicines are an opportunity for health systems (HS) and patients.

Aim and Objectives

- ✓ Aim: to evaluate use and cost evolution of adalimumab in a local hospital over last eight years.
- ✓ Biosimilar adalimumab was incorporated in 2019.


Materials and Methods

- ✓ Data collection: from January 2016 to July 2023.
- ✓ Number of 80 mg adalimumab syringes was multiplied by two in order to be able to add to 40 mg units.
- ✓ Consumption until June 2023 was extrapolated until December 2023 in order to compare values with complete years.
- ✓ Group different presentations of original brand and biosimilar molecules available and cost associated.


Results

- ✓ Adalimumab biosimilar was introduced in hospital at 2019 (penetration of biosimilars was 17.9% at 2019, reaching 99.6% at 2023).
- ✓ Consumption **adalimumab units (2016 to 2018)**, decrease slightly from 2,424 to 2,224 (-8.1 %), and also their **cost** dropped slightly, from 1,070,460 to 1,053,300 euros (-1.60%).
- ✓ Consumption **adalimumab units (2019 to 2023)**, increases from 3,317 to 6,004 units (+81.0%) with an absolute **cost** reduction of 752,553 euros (-72.6%).

Adalimumab units (2016-2023)



Adalimumab cost (euros) (2016-2023)



Adalimumab consumption increased +147.7% over past 8 years.

Adalimumab cost has decreased by -75,7% over past 8 years.

Conclusion and Relevance

- ✓ Innovation in biological therapies, has grown significantly during last years.
- ✓ Involvement of different clinical services with biosimilar molecules has led to **significant savings (-75,7%)** despite **increase in units used (+147.7%)**.
- ✓ Commercialisation of **biosimilar molecules**:
 - ✓ promote **system's sustainability**,
 - ✓ increase access to a **greater number of patients**,
 - ✓ allow continued **incorporation of innovative molecules**.

